… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … “The visual field improvements observed indicate that RNA therapy could potentially be used to treat early stage … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher syndrome and retinitis pigmentosa expected to start by yea
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the … 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … to be diligent with our capital, as we work to advance RNA therapies for individuals with high unmet need in genetic … About Sepofarsen Sepofarsen (QR-110) is an investigational RNA therapy designed to restore vision in Leber congenital …
Top-line data from pivotal Phase 2/3 Illuminate trial of sepofarsen for CEP290-mediated LCA10 anticipated late Q1/early Q2 2022
Five-target collaboration with Lilly highlights significant potential of ProQR’s Axiomer® RNA base-editing pla
… to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today reported its … Illuminate trial and is a first-in-class investigational RNA therapy designed to address the underlying cause of Leber … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …
ProQR Therapeutics today announced virtual poster presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO) held November 13-15, 2020.
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … congenital amaurosis 10 (LCA10) and the investigational RNA therapy for LCA10, sepofarsen experience to date. The … to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare …